** Shares of drugmaker BridgeBio Pharma BBIO.O rise 7.08% to $39 after market
** Co posts Q1 Attruby sales of $36.7 million, beating estimates of $13.10 million, according to data compiled by LSEG
** Attruby is used to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM), in which faulty transthyretin proteins accumulate in the heart and can cause the organ to fail
** As of April 25, 2,072 unique patient prescriptions for Attruby have been written by 756 healthcare providers since FDA approval in November 2024
** Attruby launch continues to be strong so far and has raised market expectations — BMO Capital Markets
** Stock up ~32% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.